Tesamorelin is a stabilized growth hormone-releasing hormone (GHRH) analogue used in endocrine-signaling and receptor-response research. The original overview of this page asks three questions: GHRH-receptor agonist design, the stabilizing sequence modification, and the need for identity, purity, and time-course controls.
Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.
GHRH-analogue identity
Wang and Tomlinson reviewed tesamorelin as a human growth hormone-releasing factor analogue (Wang and Tomlinson, 2009). In the clinical-research papers cited below, tesamorelin is identified as a GHRH / growth hormone-releasing factor analogue, including as GHRH(1-44) in a later pooled analysis (Falutz et al., 2010). That identity places tesamorelin in the GHRH-receptor family, not in the ghrelin-receptor (GHSR) family used by ipamorelin. See What Is Ipamorelin? and CJC-1295 vs Sermorelin vs Ipamorelin.
Sermorelin is a name for GHRH(1-29). Tesamorelin should not be filed as if it were the same fragment. A comparison of the three names is at Sermorelin vs Ipamorelin vs Tesamorelin.
Citation flag. The original page refers to a stabilizing sequence modification. The verified sources used here identify tesamorelin as a GHRH analogue. A peer-reviewed chemistry or methods paper that we independently confirmed for the exact N-terminal modification chemistry is not cited in this draft, so that structural detail is not restated beyond the analogue identification in the papers below.
Published endocrine and body-composition observations — and their limits
Falutz and colleagues reported that tesamorelin, described as a growth hormone-releasing factor analogue, reduced visceral adipose tissue and improved lipid measures relative to placebo in a randomized 26-week study of people with HIV and abdominal fat accumulation, with an increase in circulating IGF-I and no significant differences in the glycemic measures reported in that paper (Falutz et al., 2007). A later pooled analysis of two phase 3 trials reported a similar visceral-fat reduction versus placebo and described maintenance of that reduction in participants who continued tesamorelin in a safety-extension phase (Falutz et al., 2010).
Those papers are published clinical-research findings in a defined patient population. They are not a protocol for laboratory or personal use, they do not provide administration guidance, and they do not describe the lot offered on a current quotation. Results reported for tesamorelin should not be filed under sermorelin, CJC-1295, or ipamorelin.
Falutz et al. (2010) also use the investigational designation TH9507. If a quotation, label, or report uses that name, it should be reconciled with the tesamorelin identifier in the same file rather than treated as a second, undocumented analogue. IGF-I and visceral-adipose-tissue measures in those papers are endpoints of the trials they describe. A laboratory brief that uses related endocrine readouts still has to specify tesamorelin, not a neighboring GHRH fragment, as the material under test.
Identity, purity, and time-course controls
Because GHRH-analogue experiments are time-dependent, the brief should state the analogue, the sampling window, and the specification being purchased. A purity percentage does not answer whether the material is tesamorelin rather than another GHRH fragment. What Is a Peptide COA?, How to Read a Peptide COA, Third-Party Peptide Testing, Explained, and lot traceability apply independently to this row.
Tesamorelin appears in Velnacor’s research-material catalog (internal product record, slug tesamorelin), as does a combination SKU with ipamorelin. There is not a standalone public landing page for every catalog name; use the product directory and the COA Library, then confirm the exact SKU and current-lot documents in the inquiry. For packing at supply scale, see wholesale peptides.
Selected published literature
- Wang Y, Tomlinson B. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opinion on Investigational Drugs. 2009;18(3):303-310. doi:10.1517/13543780802707658. PubMed 19243281. Review article; cited for analogue identity.
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375. PubMed 18057338. Cited as published clinical-research observations, not as a use instruction.
- Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291-4304. doi:10.1210/jc.2010-0490. PubMed 20554713. Cited as published clinical-research observations, not as a use instruction.
Sourcing notes for qualified buyers
Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.
Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.
Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.